"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Cancer Center of Mesquite conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 15 clinical trials were completed, i.e. on average, 187.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Cancer Center of Mesquite" #1 sponsor was "US Oncology Research" with 9 trials, followed by "Bristol-Myers Squibb" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "NSABP Foundation Inc" with 2 trials sponsored and "Point Therapeutics" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Cancer Center of Mesquite" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "US Oncology Research" with 2 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Texas Cancer Center of Mesquite" are "Metastatic Breast Cancer" (7 trials), "Breast Cancer" (5 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Non-Small Cell Lung Cancer" (2 trials) and "Prostate Cancer" (2 trials). Many other conditions were trialed in "Texas Cancer Center of Mesquite" in a lesser frequency.

Most popular intervention types in "Texas Cancer Center of Mesquite" are "Drug" (26 trials), "Other" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (5 trials), "Carboplatin" (3 trials), "Cyclophosphamide" (3 trials), "Doxorubicin" (3 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Cancer Center of Mesquite" are 18 trials for "All" genders, 7 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Cancer Center of Mesquite". undefined are not yet recruiting, undefined are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Texas Cancer Center of Mesquite, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Cancer Center of Mesquite, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".